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Abstract
Since the original descriptions of hedonistic homeostatic dysregulation syndrome and pathological
gambling in Parkinson’s disease, impulse control disorders, such as compulsive spending, punding, or
binge eating, are increasingly recognized. Although the term hedonistic homeostatic dysregulation
syndrome has been supplanted by the concept of the dopamine dysregulation syndrome, the features
of severe dyskinesias, cyclical mood disorder with hypomania or manic psychosis, and impairment of
social and occupational functioning in the setting of increased intake of antiparkinson therapy remain.
At this time, impulse control disorder is defined as maladaptive behaviors that emerge with disease
progression and increasing antiparkinson medications. These behaviors may be disruptive, such as
punding, or destructive, such as compulsive spending, gambling, binge eating, or hypersexuality.
Introduction and context
It has long been recognized that treatment of the motor
symptoms of Parkinson’s disease (PD) with dopamine
replacement therapy (DRT) may be associated with
psychiatric disturbances [1]. Additional behaviors, char-
acterized by impulsivity and/or compulsivity, include
pathological gambling, hypersexuality, compulsive
shopping, binge eating, punding, and overuse of DRT
[2–8]. In addition, overuse of DRT has been referred to as
homeostatic hedonistic dysregulation (HHD) or dopa-
mine dysregulation syndrome (DDS) [9,10]. In DDS/
HHD, patients inappropriately consume more dopami-
nergic medication than is required to adequately control
motor symptoms and often experience significant
disruption of social and employment activities [11].
Whereas disruptiveor compulsive behaviors appear to be
linked to levodopa replacement therapy, destructive
behaviors are more often associated with behavioral
addiction, predominantly in PD patients using dopa-
mine agonists [8,12]. Features associated with these
behaviors include early age of onset, longer duration of
disease, family history of psychiatric disorders, depres-
sion, or prior history ofgambling. The majority of reports
indicate that the onset of these behaviors is associated
withtheuseofdopamineagonistseitherasmonotherapy
or in addition to levodopa rather than with the use of
levodopa alone. Patients with binge eating disorder
usually have other behavioral addictions, including
pathological gambling, compulsive shopping, hyper-
sexuality, and punding, as well as a history of weight
control issues [5]. The abnormal behaviors of hypersexu-
ality range from markedly increased sexual drive to rare
reports of paraphilia [8]. These symptoms appear to be
more common in men with early-onset PD. Unlike other
destructive behaviors, hypersexuality has been associated
with levodopa, dopamine agonists or selegiline, and a
history of alcohol or tobacco addiction [8].
Recent advances
Phenomenology: impulse control disorders
The true prevalence of impulse control disorder (ICD)
has yet to be defined, but the development of these
symptoms is correlated with age, disease duration, a
prior history of depression or drug abuse, and a number
of other factors (Table 1). Screening of 272 consecutive
PD patients revealed a prevalence rate for pathological
gambling, hypersexuality, or compulsive shopping of 4%
and a lifetime prevalence rate of 6.6 to 9.1% [13,14].
However, the DOMINION study (Impulse Control
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pexole and Other Agents), a prospective multi-centered
trial to assess the frequency of these behaviors in more
than 3,000 subjects, has found that at least one ICD was
identified in 13.6% of patients, while 4.9% of patients
had multiple behaviors. The frequencies of single ICDs
reported for the entire population were: compulsive
buying (5.7%), compulsive gambling (5.0%), binge-
eating disorder (4.3%), and compulsive sexual behavior
(3.5%) [15].
Although the majority of the reports note an association
of these behaviors with the use of dopamine agonists,
some cases do occur in patients on levodopa alone. It has
also been argued that ICD behaviors may be indepen-
dent of DRT and secondary to disease severity and
progression [8,13,14].
Dopamine dysregulation syndrome
Approximately 4% of PD patients on DRT are reported to
overuse dopaminergic medications. Compulsive medi-
cation dosing has been noted to be more prevalent in
men [14,16]. In addition, a history of alcohol abuse,
mood disorders, and family history of psychiatric
problems may be predisposing factors. Diagnostic
criteria have been proposed for DDS and include at
least a 6-month history of the need for increased doses of
DRT, pathological drug use, impairment in social or
employment functions, affective disorders, and a with-
drawal state when medications are decreased [10,11].
Some individuals with DDS meet diagnostic criteria for
substance dependence [13,14].
Punding
Punding refers to aimless repetitive activity often
involving manipulations of a familiar object. The term
is borrowed from the vernacular of Swedish intravenous
amphetamine addicts exhibiting this behavior and is
loosely translated as ‘blockhead’. This behavior was first
suggested as being levodopa-induced by Dr Joseph
Friedman. Now punding is defined as compulsive
performance of repetitive tasks, such as assembly/
disassembly, collecting things, or sorting household
objects [17–19]. Other behaviors, ‘hobbyisms’,t h a t
may represent variants of punding include excessive
humming or singing, inordinate writing, paper shuffling,
blogging/journaling, doodling, painting, walkabouts,
and reciting long meaningless soliloquies without an
audience. Interestingly, performance of these behaviors
may be linked to increased synaptic dopamine, since
amphetamine, cocaine, and levodopa share a presynap-
tic mechanism. In addition, these activities seem to be
more prominent during ‘on time’ and ‘on time with
dyskinesias’. These repetitive behaviors are associated
with high dosages of DRT (greater than 800 levodopa
equivalents per day) and seem to occur in the ‘on-state’.
Pathogenesis
The anatomic substrate for ICD is not fully elucidated.
The direct pathway, mediated through D1 dopamine
receptors, is associated with the development of motor
symptoms of PD, such as wearing off and dyskinesias.
The D2 dopamine receptor mediates neuronal activity in
the indirect pathway and has a prominent role in ICD in
PD and in addiction disorders [8]. Within the D2-type
receptor family are D3 receptors, which reside within the
ventral striatum/nucleus accumbens and modulate non-
motor circuits. These non-motor circuits include: the
dorsolateral prefrontal cortex, regulating executive func-
tion; the lateral orbitofrontal cortex, modulating socially
appropriate behavior and mood; and the anterior
cingulate cortex, initiating activity and maintaining
interest [20,21]. Given the homologies of binding sites
between levodopa and amphetamine, receptor changes
in PD may underlie the disruptive behaviors of DRT-
related compulsivity, similar to punding in addiction
disorders. Destructive behaviors may arise in the
continuum of neurodegeneration, levodopa-related
changes, and the addition of variably selective D3/D2
dopamine agonists [8].
Table 1. Risk factors for impulse control disorders (ICD) [23]
Risk factors for ICD Possible ICDs Definite ICDs
Diagnosis prior to 50 years of age
Diagnosed for >5 years
Male gender
History of depression, anxiety, or bipolar disorder
Prior drug/alcohol abuse
Prior gambling or other behavioral addiction
Family history of mental illness
Family history of drug/alcohol addiction
Dyskinesias
Levodopa or equivalent dopaminergic therapy dosages >1,000 mg/day
Dopamine agonist therapy
Reported change in personality or behavior
Increased secrecy
Increased time at hobbies or work












ICD, impulse control disorder.
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In July 2007, the first international meeting devoted to
this topic was held in Toronto [22]. Nearly 100 clinicians
and researchers from six countries met in this 2-day
workshop to discuss a wide range of topics, including
punding, behavioral addiction, addiction to DRT, and
the seemingly paradoxical observations concerning the
use of deep brain stimulation in this population. The
faculty for the seven scientific sessions represented
subspecialty interest in neurology, psychiatry, addiction,
and neuroscience, and a poster session provided addi-
tional new information concerning this interesting
behavioral syndrome. The major outcomes from this
meeting were: (1) defining the clinical features of this
syndrome [23], and (2) identifying an unmet need for
validated clinical assessments in this population of PD
patients [24].
Implications for clinical practice
Treatment of ICD requires early recognition of the
symptoms. Because of the potential for these addictive
symptoms to rapidly escalate, adequate and consistent
patient education is important, particularly when intro-
ducing a new dopaminergic therapy or increasing the
dosage of a dopaminergic agent. If any symptoms of ICD
are recognized, inquiry for other symptoms is important
because, for instance, symptoms of hypersexuality may
require treatment strategies that differ to those of
compulsive spending or punding [8,25].
The initial intervention is usually a function of reducing
the last medication changed in treating PD. In the initial
reports of pathological gambling, the behaviors emerged
after increasing dopamine agonist therapy. In the
majority of these instances, reduction or discontinuation
of this agent resulted in behavior benefit. In general,
patients with compulsive gambling, spending, or eating
usually respond to dopamine agonist reduction, whereas
patients with punding benefit from levodopa reduction.
The population with problems resulting from hyperhe-
donistic behaviors may benefit from reduction of either
dopamine agonist or levodopa. Clearly, DDS requires
careful reduction of dopaminergic therapy [25].
Additional treatment interventions are highly anecdotal
but include treatment of comorbid depression with
selective serotonin-reuptake inhibitor or other antide-
pressants or bipolar symptoms with lithium or anti-
psychotic agents, such as quetiapine or clozapine.
Preliminary study with acamprosate, a synthetic struc-
tural analogue of the amino acid neurotransmitter
gamma-aminobutyric acid (GABA) approved for the
treatment of alcohol abuse, suggests that this agent may
be helpful in treating compulsive eating and sweet
craving. Counselling may be important in the setting of
sexual, eating, or gambling addictions. Lay support
groups for problem addictions (for example, Gamblers
Anonymous) have been suggested frequently, because of
additional advice regarding the financial options impor-
tant in this recovery [25].
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(Uxbridge, Middlesex, UK) to provide advice for tools to
monitor the development of impulse control disorder
symptoms related to ropinirole and ropinirole XL. He
also served on the steering committee for DOMINION,
a trial sponsored by Boehringer-Ingelheim (Ingelheim,
Germany), to assess the frequency of impulse control
disorders in a Parkinson’s disease population.
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